Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 in Chronic Pancreatitis (CP) Patients With Exocrine Pancreatic Insufficiency (EPI)

NCT00788593 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT00788593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00788593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 in Chronic Pancreatitis (CP) Patients With Exocrine Pancreatic Insufficiency (EPI)
Lead sponsor
Forest Laboratories
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2008
Completion date
March 31, 2009
Enrollment
82 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

chronic pancreatitis, exocrine pancreatic insufficiency